Similar articles

• Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes.

  Eddy DM, Schlessinger L, Kahn R. Eddy DM, et al. Ann Intern Med. 2005 Aug 16;143(4):251-64. doi: 10.7326/0003-4819-143-4-200508160-00006. Ann Intern Med. 2005. PMID: 16103469
• Summaries for patients. The cost-effectiveness of strategies to prevent type 2 diabetes.

  [No authors listed] [No authors listed] Ann Intern Med. 2005 Mar 1;142(5):I28. doi: 10.7326/0003-4819-142-5-200503010-00002. Ann Intern Med. 2005. PMID: 15738446 No abstract available.
• The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance.

  Herman WH, Hoerger TJ, Brandle M, Hicks K, Sorensen S, Zhang P, Hamman RF, Ackermann RT, Engelgau MM, Ratner RE; Diabetes Prevention Program Research Group. Herman WH, et al. Ann Intern Med. 2005 Mar 1;142(5):323-32. doi: 10.7326/0003-4819-142-5-200503010-00007. Ann Intern Med. 2005. PMID: 15738451 Free PMC article.
• Lifetime health consequences and cost-effectiveness of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in Spain.

  Shearer AT, Bagust A, Ampudia-Blasco FJ, Martínez-Lage Alvarez B, Pérez Escolano I, París G. Shearer AT, et al. Pharmacoeconomics. 2006;24 Suppl 1:49-59. doi: 10.2165/00019053-200624001-00005. Pharmacoeconomics. 2006. PMID: 16800162 Review.
• Clinical Inquiry: Does metformin prevent diabetes in at-risk adults?

  Mangahas T, Huang G, Neher J, Safranek S. Mangahas T, et al. J Fam Pract. 2013 Aug;62(8):436-7. J Fam Pract. 2013. PMID: 24143338 Review. No abstract available.